Where We Operate

Care that’s coming to your corner of the country.

Cope Now delivers clinician‑guided prescription cannabinoid care by secure telehealth — and we’re expanding fast. Find your state below.

Scroll

From a single state to coast to coast.

Licensed, compounded, and delivered wherever care is available.

Availability

Live in 6 states — 44 more on October 1.

Available today in 6 states. The rest go live October 1.
⚲
Available now Coming October 1
AlabamaOctober 1
AlaskaOctober 1
ArizonaAvailable
ArkansasOctober 1
CaliforniaOctober 1
ColoradoAvailable
ConnecticutOctober 1
DelawareOctober 1
FloridaAvailable
GeorgiaOctober 1
HawaiiOctober 1
IdahoOctober 1
IllinoisOctober 1
IndianaOctober 1
IowaOctober 1
KansasOctober 1
KentuckyOctober 1
LouisianaOctober 1
MaineOctober 1
MarylandOctober 1
MassachusettsOctober 1
MichiganOctober 1
MinnesotaOctober 1
MississippiOctober 1
MissouriOctober 1
MontanaOctober 1
NebraskaOctober 1
NevadaOctober 1
New HampshireOctober 1
New JerseyOctober 1
New MexicoOctober 1
New YorkOctober 1
North CarolinaOctober 1
North DakotaOctober 1
OhioOctober 1
OklahomaOctober 1
OregonOctober 1
PennsylvaniaOctober 1
Rhode IslandOctober 1
South CarolinaOctober 1
South DakotaAvailable
TennesseeOctober 1
TexasOctober 1
UtahAvailable
VermontOctober 1
VirginiaOctober 1
WashingtonOctober 1
West VirginiaOctober 1
WisconsinOctober 1
WyomingAvailable
Availability is based on where you are physically located at the time of your appointment, not your billing address. Telehealth expansion is subject to applicable licensure and regulatory approvals.
The road ahead

Going nationwide on October 1.

We’re rolling out state by state, and on October 1 clinician‑guided care opens to every remaining state. Check your eligibility now and you’ll be ready the moment your state goes live.

Start here

See if you’re eligible — it’s free.

A short screening confirms the basics. If your state is live, you can move forward today; if not, you’ll be first in line when it opens.

Check Your Eligibility
Important safety information

Prescription cannabinoid therapies require clinical oversight.

Common side effects

Prescription cannabinoid therapies may cause drowsiness, fatigue, changes in appetite, diarrhea, and dry mouth. Effects vary by patient, dose, and formulation.

Drug‑interaction risk

CBD can affect how the body metabolizes other medications through cytochrome P450 liver enzymes, which may alter the effectiveness or safety of prescriptions including blood thinners, anti‑seizure medications, and some antidepressants. Disclose all current medications and supplements to your clinician during evaluation.

Liver‑enzyme monitoring

Elevated liver enzymes have been observed in clinical research on CBD, particularly at higher doses. Your clinician may recommend liver‑function testing before or during your protocol. Patients with existing liver conditions require additional review.

Not FDA‑approved

Compounded cannabinoid formulations are prepared under FDA 503A regulations for individual patients. They are not FDA‑approved drugs and have not been evaluated by the FDA for safety, efficacy, or quality in the same way as commercial pharmaceuticals. Compounded medications are prescribed when a clinician determines a commercially available product is not appropriate for a specific patient.

This information is provided for educational purposes and does not replace clinical advice. Speak with a licensed clinician before beginning any cannabinoid protocol. Telehealth currently available in Colorado only. Individual results vary. Prescription decisions are made solely by a licensed clinician and are never automatic.